All In Biotech

Drug Trial Radar · NCT07811518

Latent Infection Freshmen Tracking for Tuberculosis

Real-World Implementation and Effectiveness of Tuberculosis Preventive Treatment in School Health Services in China

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Aug 15, 2022

Primary completion

Aug 31, 2026

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Meishan Municipal Center for Disease Prevention and Control
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 24 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn whether taking short-course preventive treatment in high school and college freshmen with strong positive tuberculosis (TB) skin tests can safely and effectively protect them from developing active TB over a 3-to-4-years period. Main question: Does taking short-course preventive treatment reduce the risk of active TB in freshmen who have strong positive TB skin tests? All freshmen across 26 schools in Meishan City, Sichuan Province, China were screened for TB. Among them, the students with strong positive skin tests (indicating latent TB infection) and no active disease entered the study. Students voluntarily chose to either take a 3-month short-course preventive treatment under campus medical supervision or receive routine health observation without medication. Researchers tracked all participants for 3 to 4 years to monitor who developed active TB and evaluate the treatment's safety and effectiveness.

Conditions

  • Latent Tuberculosis Infection (LTBI)
  • Tuberculosis (TB)

Interventions

  • tuberculosis preventive treatmentDrug

    3HR Regimen: Isoniazid (INH) + Rifampin (RIF), once daily, 90 total doses (3 months); 3H2P2 Regimen: Isoniazid (INH) + Rifapentine (RPT), twice weekly, 24 total doses (3 months)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident active tuberculosisTime frame: Up to 4 years post-baseline screening (from T0 through August 31, 2026)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

  • Meishan Municipal Center for Disease Prevention and Control

    Meishan, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.